Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00103-020-03229-1 http://scihub22266oqcxt.onion/10.1007/s00103-020-03229-1 33034695!7545799!33034695     free     free     free       Bundesgesundheitsblatt+Gesundheitsforschung+Gesundheitsschutz 2020 ; 63 (11): 1396-1402 Nephropedia Template TP {{tp|p=33034695|t=2020. Monoklonale Antikorper zur antiinfektiven Therapie |pdf=|usr=}}{{33034695}} gab.com Text Monoklonale Antikorper zur antiinfektiven Therapie JO: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz http://www.kidney.de/pget.php?&tw=1&pmid=33034695 #FOAvip Sera of animal origin and hyperimmunoglobulins have dominated serum therapy for a century. Although numerous monoclonal antibodies (MABs) have been developed since the end of the 1980s, particularly for the treatment of immunological and oncological diseases, it will take 20 years before the first anti-infective MAB is approved in the European Union. Interestingly, to combat the COVID-19 pandemic, numerous MABs, which are approved in particular for immunological indications, are currently being used to treat the consequences of SARS-CoV?2 infection, such as pneumonia or hyperimmune reactions.The approved monoclonal antibodies for the treatment of infectious diseases are presented here. In addition, an overview of the current developments, in particular in the treatment of SARS-CoV?2 infection, is provided. Twit Text FOAVip Monoklonale Antikorper zur antiinfektiven Therapie ????Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz http://www.kidney.de/pget.php?&tw=1&pmid=33034695 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33034695 #FOAvip English Wikipedia <ref>{{Cite pmid|33034695}}</ref> Monoklonale Antikorper zur antiinfektiven Therapie #MMPMID33034695 Klug B; Schnierle B; Trebesch I Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2020[Nov]; 63 (11): 1396-1402 PMID33034695show ga Sera of animal origin and hyperimmunoglobulins have dominated serum therapy for a century. Although numerous monoclonal antibodies (MABs) have been developed since the end of the 1980s, particularly for the treatment of immunological and oncological diseases, it will take 20 years before the first anti-infective MAB is approved in the European Union. Interestingly, to combat the COVID-19 pandemic, numerous MABs, which are approved in particular for immunological indications, are currently being used to treat the consequences of SARS-CoV?2 infection, such as pneumonia or hyperimmune reactions.The approved monoclonal antibodies for the treatment of infectious diseases are presented here. In addition, an overview of the current developments, in particular in the treatment of SARS-CoV?2 infection, is provided. |*Antibodies, Monoclonal/therapeutic use[MESH] |*Coronavirus Infections[MESH] |*Pandemics[MESH] |*Pneumonia, Viral[MESH] |Animals[MESH] |Antibodies, Viral[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |Germany[MESH] |Humans[MESH]Monoklonale Antikorper zur antiinfektiven Therapie (epmc).pdf DeepDyve Pubget Overpricing